Ambrilia Biopharma found that its immunoassay for the diagnosis and prognosis of prostate cancer acted as independent predictive markers of a potential recurrence of prostate cancer. The study was conducted in prostate cancer patients who had undergone radical prostatectomy. PSP94 (prostate secretory protein of 94 amino acids, bound/free ratio) as well as PSPBP (PSP binding protein) were compared to initial total prostate specific antigen (PSA), Gleason score, and surgical margin status.
"We have previously shown the diagnostic potential of our PSP94 immunoassay to reduce the number of unnecessary biopsies," points out Hans J. Mader, president and CEO of Ambrilia, “and are very pleased to now also demonstrate the prognostic value of PSP94 as a very versatile and excellent serological marker to be used in combination with PSA for predicting the recurrence of prostate cancer following surgery and/or other treatments.”
The study was published in the October 15th issue of Clinical Cancer Research. Serum samples were obtained from 185 patients with localized prostate cancer prior to undergoing radical prostatectomy. Patients were followed for biochemical relapse for a median of four years. Pretreatment total PSP94, free PSP94, and PSP94 binding protein levels were correlated with clinical variables including total PSA, Gleason score, surgical margin status, and clinical stage.
Biochemical relapse was observed in 31 patients and the recurrence risk was significantly predicted by the clinical variables (all p less than 0.001). In addition, it was found that PSPBP was inversely associated with recurrence risk (p equals 0.008), while the ratio of bound/free PSP94 was directly associated with recurrence risk (p equals 0.005). Ambrilia Biopharma hence concludes that these are independent prognostic markers for relapse following radical prostatectomy for prostate cancer.